These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26351632)

  • 21. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.
    Ho AY; Gupta G; King TA; Perez CA; Patil SM; Rogers KH; Wen YH; Brogi E; Morrow M; Hudis CA; Traina T; McCormick B; Powell SN; Robson ME
    Cancer; 2012 Oct; 118(20):4944-52. PubMed ID: 22392492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy and differential invasive breast cancer specific survival in elderly women.
    Kaplan HG; Malmgren JA; Atwood MK
    J Geriatr Oncol; 2013 Apr; 4(2):148-56. PubMed ID: 24071540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients.
    Gómez HL; Castañeda CA; Vigil CE; Vidaurre T; Velarde RG; Cruz WR; Pinto JA; Suazo JF; Garcés MR; Neciosup SP; Vallejos CS
    Hematol Oncol Stem Cell Ther; 2010; 3(3):109-15. PubMed ID: 20890067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
    De Camargo Cancela M; Comber H; Sharp L
    Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
    Kim SJ; Masuda N; Tsukamoto F; Inaji H; Akiyama F; Sonoo H; Kurebayashi J; Yoshidome K; Tsujimoto M; Takei H; Masuda S; Nakamura S; Noguchi S
    Cancer Lett; 2014 Dec; 355(2):217-23. PubMed ID: 25218592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.
    Livi L; Meattini I; Saieva C; Franzese C; Di Cataldo V; Greto D; Franceschini D; Scotti V; Bonomo P; Nori J; Sanchez L; Vezzosi V; Bianchi S; Cataliotti L; Biti G
    Cancer; 2012 Jul; 118(13):3236-43. PubMed ID: 22028054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.
    Henderson J; Adams P; Barber K
    Clin Breast Cancer; 2019 Jun; 19(3):e475-e480. PubMed ID: 30852142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
    Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance following breast conservation therapy with or without irradiation in breast cancer patients.
    Tamaki K; Tamaki N; Kamada Y; Uehara K; Ohuchi N; Miyashita M; Ishida T; Sasano H
    Jpn J Clin Oncol; 2013 Mar; 43(3):251-7. PubMed ID: 23277499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.